The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer
Open accessThe DOI matches its Crossref record; 124 of the 125 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 receptor (GLP-1R) agonists have garnered significant attention for their therapeutic potential in addressing the interconnected health challenges of diabetes, obesity, and cancer. The role of GLP-1R in type 2 diabetes mellitus (T2DM) is highlighted, emphasizing its pivotal contribution to glucose homeostasis, promoting β-cell proliferation, and facilitating insulin release. GLP-1R agonists have effectively managed obesity by reducing hunger, moderating food intake, and regulating body weight. Beyond diabetes and obesity, GLP-1R agonists exhibit a multifaceted impact on cancer progression across various malignancies. The mechanisms underlying these effects involve the modulation of signaling pathways associated with cell growth, survival, and metabolism. However, the current literature reveals a lack of in vivo studies on specific GLP-1R agonists such as semaglutide, necessitating further research to elucidate its precise mechanisms and effects, particularly in cancer. While other GLP-1R agonists have shown promising outcomes in mitigating cancer progression, the association between some GLP-1R agonists and an increased risk of cancer remains a topic requiring more profound investigation. This calls for more extensive research to unravel the intricate relationships between the GLP-1R agonist and different cancers, providing valuable insights for clinicians and researchers alike.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1R, a core member of the GPCR family, is widely present on the surfaces of various cells in the human body.1,2”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Ong, K. L., Stafford, L. K., McLaughlin, S. A., Boyko, E. J., Vollset, S. E., Smith, A. E., Dalton, B. E., Duprey, J., Cruz, J. A., Hagins, H., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01301-6 · Cited by 6,146
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
Chooi, Y. C., Ding, C., & Magkos, F. (2019) · Metabolism · doi:10.1016/j.metabol.2018.09.005 · Cited by 2,737
Colberg, S. R., Sigal, R. J., Fernhall, B., Regensteiner, J. G., Blissmer, B. J., Rubin, R. R., Chasan-Taber, L., Albright, A. L., & Braun, B. (2010) · Diabetes Care · doi:10.2337/dc10-9990 · Cited by 1,955
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art
Nauck, M. A., Quast, D. R., Wefers, J., & Meier, J. J. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2020.101102 · Cited by 1,647
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
Meier, J. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.140 · Cited by 1,311
Research works printed but not linked: 6
- Johnson, L. R., Barret, K. E., Gishan, F. K., Merchant, J. L., Said, H. M., & Wood, J. D. (2006). Physiology of the gastrointestinal tract;; Vol. 1–2.
- Collins, L., & Costello, R. A. (2023). Glucagon-like peptide-1 receptor agonists. StatPearls. 31855395
- Koehler, J. A., Kain, T., & Drucker, D. J. (2011). Glucagon-like peptide-1 receptor activation inhibits growth and augments apoptosis in murine CT26 colon cancer cells. Endocrinology,152,. 10.1210/en.2011-1201 21771884 · DOI · Paper page
- Iwaya, C., Nomiyama, T., Komatsu, S., Kawanami, T., Tsutsumi, Y., Hamaguchi, Y., Horikawa, T., Yoshinaga, Y., Yamashita, S., Tanaka, T., et al. (2017). Exendin-4, a glucagonlike peptide-1 receptor agonist, attenuates breast cancer growth by inhibiting NF-ΚB activation. Endocrinology, 158, 4218–4232. 10.1210/EN.2017-00461 29045658 · DOI · Paper page
- Tanaka, Y., Iwaya, C., Kawanami, T., Hamaguchi, Y., Horikawa, T., Shigeoka, T., Yanase, T., Kawanami, D., & Nomiyama, T. (2022). Combined treatment with glucagon-like peptide-1 receptor agonist exendin-4 and metformin attenuates breast cancer growth. Diabetology International, 13, 480–492. 10.1007/s13340-021-00560-z 35693999 PMC9174406 · DOI
- Tsutsumi, Y., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Terawaki, Y., Tanaka, T., Murase, K., Motonaga, R., Tanabe, M., & Yanase, T. (2015). Combined treatment with exendin-4 and metformin attenuates prostate cancer growth. PLoS One, 10, e0139709. 10.1371/journal.pone.0139709 26439622 PMC4595004 · DOI
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Münte, E., & Hartmann, P. (2025) · Biomolecules · doi:10.3390/biom15040469 · Cited by 89
Levy, S. M., Attia, A. S., Elshazli, R. M., Abdelmaksoud, A., Tatum, D. M., Aiash, H., & Toraih, E. A. (2024) · Cancers · doi:10.3390/cancers17010078 · Cited by 72
“The widespread expression of GLP-1 receptors in various tissues, including the gastrointestinal tract, pancreatic islets, thyroid gland, kidney, heart, lungs, and central nervous system [8,9], suggests a broader physiological role beyond metabolic regulation [10,11].”
Ungvari, Z. I., Bartha, Á., Ungvari, A., Fekete, M., Bianchini, G., & Győrffy, B. (2025) · GeroScience · doi:10.1007/s11357-024-01494-5 · Cited by 51
“Beyond their well-documented metabolic benefits, there is a growing interest in the potential effects of GLP1R agonists on cancer biology [3–9].”
Advances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
“Glucagon-like peptide-1 receptor (GLP-1R), a class B G-protein-coupled receptor (GPCR), is broadly expressed on the surfaces of various cells, including the pancreas, intestine and brain [8].”
How ‘miracle’ weight‐loss semaglutide promises to change medicine but can we afford the expense?
Weiskirchen, R., & Lonardo, A. (2025) · British Journal of Pharmacology · doi:10.1111/bph.70003 · Cited by 30
“…semaglutide mimics the physiological actions of endogenous GLP-1, leading to several beneficial effects that contribute to its therapeutic use in managing obesity T2D, and further having beneficial effects on cardiovascular risk factors and cancer (Ibrahim et al., 2024; Raza et al., 2024).”
Engineered GLP-1R-targeting nanoplatforms: multimodal therapeutics in human diseases
Zeng, J., Tang, X., Qin, D., Yu, L., Zhou, X., Chi, F., Mi, J., Pan, H., Wu, J., Huang, B., et al. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03677-4 · Cited by 28
Semaglutida: Uma análise dos efeitos do uso no combate à obesidade
Ribeiro, L. V. N., Dias, E. D. S., de Azevedo, P. F. S., de Oliveira, P. H. D. S. C., Cordeiro, G. G., Pinheiro, H. S., & Leão, K. A. (2024) · E-Acadêmica · doi:10.52076/eacad-v5i2.553 · Cited by 24
GLP-1 Receptor Agonists Plus Progestins and Endometrial Cancer Risk in Nonmalignant Uterine Diseases
Yen, T., Hsieh, T. Y. J., Lee, G. Y., Toy, E. P., Wei, J. C.-C., & Tanner, E. J. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.58205 · Cited by 22
Wang, C., Wu, Z., Zhou, J., Cheng, B., & Huang, Y. (2025) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-025-06154-5 · Cited by 22
“The glucagon-like peptide-1 receptor (GLP-1R), a member of the G protein-coupled receptor (GPCR) family, is expressed in multiple tissues, including the pancreas, lung, liver, kidney, stomach, intestine, heart, and central nervous system regions (Ibrahim et al. 2024; Zheng et al. 2024).”
Hung, C., Zeng, B., Hsu, C.-W., Chen, P., Sun, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., et al. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000003450 · Cited by 20
“On the other hand, the increased dosage of injection-form semaglutide would increase the potential pro-tumorigenic signals in the targeted cells through its constant high concentration related to the injec-tion-form designation [ 120 ] .”
Glenny, E. M., Coleman, M. F., Clutton, G. T., Riesenberg, B. P., Ho, A. N., McFarlane, T. L., Kiesel, V. A., Kucinskas, A. L., Bailey, E. G., Sanchez, K. E., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.01.20.576484 · Cited by 18
Ateiwi, Y. A., Mahmood, R. R., Wong, H. J., Low, C. E., Yau, C. E., Lee, A. R. Y. B., Eng, P. C., Lee, M., Chan, M. Y., & Sia, C. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113158 · Cited by 17
Mahadevan, A., Vosooghi, A., Arora, J. S., Kumar, R. S., Singh, G., Tsai, K. K., & Quandt, Z. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf703 · Cited by 16
Fawzy, M. S., Alenezy, A. K., Jishu, J. A., Khan, I., Dessouky, A., Abdelmaksoud, A., Limbach, K. E., & Toraih, E. A. (2025) · Cancers · doi:10.3390/cancers17091593 · Cited by 15
“GLP-1Ra medications create systemic metabolic shifts, reducing hyperinsulinemia and subsequently decreasing the availability of growth factors known to promote cancer progression [22].”
Shareef, L. G., Khalid, S. S., Raheem, M. F., Al‐Hussainy, A. F., Al-Khayyat, N. S., Arajy, A. Z. A., Noori, M. M., Qasim, M. U., & Jasim, H. H. (2024) · Cureus · doi:10.7759/cureus.71569 · Cited by 14
“GLP-1 receptor agonists (GLP-1 RAs) are now becoming recognized as very successful treatments for obesity [6].”
Intestinal L-cell mechanoreception regulates hepatic lipid metabolism through GLP-1
Gao, L., Yang, K., Zhao, Y., Zhang, J., Jiang, S., Zhang, R., He, W., Zhao, Y., Ye, Q., & Xu, G. (2025) · Science Advances · doi:10.1126/sciadv.adv3201 · Cited by 14
“Furthermore, it has been demonstrated that GLP-1R agonists act as a regulatory pathway that influences metabolic disorders ( 42 ).”
The dual burden of obesity: decoding metabolism and female reproductive endocrinology
Chen, Y., Wang, R., Zhang, N., & Xu, L. (2025) · Frontiers in Physiology · doi:10.3389/fphys.2025.1627607 · Cited by 12
Peng, L., Lai, W., Yu, S., Li, Q., Jiang, X., & Chen, G. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1551136 · Cited by 12
“GLP-1R agonists have demonstrated signi fi cant ef fi cacy in the treatment of type 2 diabetes and obesity (35).”
Discovery of Selenium-Containing Derivatives as Potent and Orally Bioavailable GLP-1R Agonists
Chen, X., Xu, S., Yang, S. C., Yu, Z.-Z., Chen, Y., Wu, H., Bao, Q., You, Q., Guo, X., & Jiang, Z. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c02616 · Cited by 11
Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis
Jamialahamdi, T., Mirhadi, E., Almahmeed, W. A., Virani, S. S., Eid, A. H., Al‐Rasadi, K., Salehabadi, S., & Sahebkar, A. (2025) · Obesity Surgery · doi:10.1007/s11695-025-07848-y · Cited by 10
“Among these actions is the well-documented role of these drugs as effective weight loss agents, demonstrating efficacy surpassing the aforementioned medications [5–10].”
Storey, K. M., Shay, L. A., Poteat, T., Pennington, K. A., & Schulz, L. C. (2025) · Reproduction · doi:10.1530/rep-25-0050 · Cited by 8
Zhang, C., Dong, G., Wu, X. Q., Chen, J., Wang, Y., Gong, L., Yang, X., Shi, Y., Gu, Z., Gao, X., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00147 · Cited by 7
Translating Metabolic Interventions into Breast Cancer Therapy: A Comprehensive Review
Chen, L., Shiao, S. L., & Yuan, Y. (2025) · Life · doi:10.3390/life15101634 · Cited by 7
“In breast cancer, various GLP-1RAs have been shown to result in a decrease in tumor size, weight, and proliferation index [94].”
Hu, Z., Tian, D., Yang, Z., Zhang, J., Zhang, L., Xu, Y., & Lu, X. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1754721 · Cited by 7
“Their varied effects also indicate their potential in addressing simultaneous metabolic disorders and liver diseases, opening the door for broader indications in liver disease treatment as clinical evidence accumulates (Ibrahim et al., 2024; Yan et al., 2023).”
A Systematic Review of the Cutaneous Adverse Effects of GLP-1 Agonists
DeVore, S., Reimer, H., Meihofer, A., Miner, K., Miranda, G., Misra, R., & Martinez, G. (2025) · ARC Journal of Dermatology · doi:10.20431/2456-0022.0802005 · Cited by 6
“Diabetes and obesity, however, are well-established risk factors for carcinogenesis, contributing to a pro-tumorigenic environment through hyperglycemia, hyperinsulinemia, chronic inflammation, and increased oxidative stress 20 .”
Are GLP-1 receptor agonists and diabetic retinopathy foes or friends?
Liu, K., Liu, S., Wang, D., & Qiao, H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101696 · Cited by 6
An, X., Duan, L., Zhang, Y., Jia, Q.-Y., Zhang, Y., & Qiao, Y. (2025) · World Journal of Diabetes · doi:10.4239/wjd.v16.i10.110174 · Cited by 6
The role of GLP-1 receptor in pain disorders and its pharmacological properties
Jing, F., Zeng, Y., Yu, Q.-L., & Fu, C. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.178345 · Cited by 6
The perspectives in obesity and type 2 diabetes therapy: the present and future of incretin therapy
Shestakova, M. V., & Bashlykova, R. O. (2025) · Terapevticheskii arkhiv · doi:10.26442/00403660.2025.10.203366 · Cited by 6
Navigating Metabolic Challenges in Ovarian Cancer: Insights and Innovations in Drug Repurposing
Mikhael, S., & Daoud, G. (2025) · Cancer Medicine · doi:10.1002/cam4.70681 · Cited by 6
“Moreover, emerging evidence suggests that glucagon-like pep- tide-1 receptor (GLP-1R) agonists, including semaglutide and liraglutide, hold a dual role in cancer biology [138].”
Farrash, W. F., & Obaid, A. A. (2025) · Diseases · doi:10.3390/diseases13090304 · Cited by 5
“Cancer is a multifactorial disease and a major public health concern worldwide, resulting from the interplay of genetic mutations and environmental factors [1–3].”
InfluentialMohtadi, S., Molavinia, S., Shariati, S., Mahdavinia, M., Dayer, D., & Farzam, F. (2025) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70584 · Cited by 5
Refaat, B., Elzubier, M., Aslam, A., Idris, S., & Farrash, W. F. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70913 · Cited by 5
Pahulu, I., Calumpit, M., Tominez, P., Shih, J. J., Ebrahimi, S., DeVille, N. V., Samoa, R. A., Moin, T., Sedrak, M. S., Valle, L., et al. (2026) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkag014 · Cited by 4
Lv, J., Zhou, L., Dai, X., Landberg, R., Meng, H., Tian, H., Zhang, S., Liu, T., Yin, X., Zhang, J., et al. (2026) · Gut Microbes · doi:10.1080/19490976.2026.2668127 · Cited by 4
GLP-1 Receptor Agonists and Primary Prevention of Cancer Therapy-Related Cardiac Dysfunction
Javaid, S. S., Hanif, M., Paulson, S., Anker, M. S., Chew, N. W., Jamil, A., Anker, S. D., DiMaio, J. M., Butler, J., & Khan, M. S. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.06.008 · Cited by 4
Zhang, S., Du, K., Gao, S., Liu, Z., Chen, L., Wu, X., & Li, L. (2025) · Human Genetics · doi:10.1007/s00439-025-02753-x · Cited by 3
“GLP1 receptor (GLP1R) serves as a therapeutic target in the obesity-diabetes-tumor triad (Ibrahim et al. 2024), due to its role in regulating key pathways involved in cell growth, survival, and metabolism, which impact cancer progression.”
Uba, A. İ. (2025) · Chemical Papers · doi:10.1007/s11696-025-04431-8 · Cited by 3
“While PAMs and orthosteric agonists have dominated GLP-1R research in diabetes and obesity therapies (Ibrahim et al. 2024; Al Qassab et al. 2025), NAMs may offer a distinct pharmacological niche with potential therapeutic implications in non-metabolic and tissue-specific contexts.”
Glucagon-Like Peptide-1 Receptor Agonist Treatment and Risk of Esophageal Cancer
Åkerström, J. H., Santoni, G., von Euler‐Chelpin, M., Birgisson, H., Ness‐Jensen, E., Kauppila, J. H., Holmberg, D., & Lagergren, J. (2025) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000003885 · Cited by 3
Correra, A., Mauriello, A., Cetoretta, V., Maratea, A. C., Riegler, L., Sarno, I. D., Giallauria, F., Guerra, F., Russo, V., & D’Andrea, A. (2026) · Pharmaceuticals · doi:10.3390/ph19020297 · Cited by 3
“Chemically, semaglutide shares 94% sequence homology with native human GLP-1 but has been engineered with specific structural modifications to overcome the pharmacokinetic limitations of the endogenous hormone [12].”
GLP-1 receptor agonist initiation and risk of colorectal cancer and colonic polyps
Mari, A. A. M., Alamin, F., Le, M. A., Rizvi, A., & Mansi, I. A. (2026) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2026.02.002 · Cited by 3
Fibrillar and Micellar Aggregation of Semaglutide and Formation of a Chiral-Imprinted Glass
Castelletto, V., de Mello, L. R., Seitsonen, J. J. T., & Hamley, I. W. (2026) · Biomacromolecules · doi:10.1021/acs.biomac.5c02669 · Cited by 3
Den, J., Vaghjiani, R. G., Hutter, M., & Klimberg, V. S. (2026) · Annals of Surgery · doi:10.1097/sla.0000000000007121 · Cited by 3
Liu, J., Chen, Z., Yang, Q., Lin, H., Wang, S., Li, M., Wang, T., Zhao, Z., Xu, M., Chen, Y., et al. (2026) · Communications Medicine · doi:10.1038/s43856-026-01379-y · Cited by 2
The GLP ‐1– miRNA network: Epigenetic control of obesity and metabolic disorders
Zhao, S., Qin, P., Wang, X. F., & You, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70551 · Cited by 2
“47,48 Nota-bly, AKT activation also promotes cell cycle progression and therefore β -cell proliferation, facilitating the continuity of functional β -cell mass, which is a significant determinant of long-term glycaemic control.”
Revisiting old drugs and drug combinations for polycythemia vera and related neoplasms
Mergen, G., & Hasselbalch, H. C. (2026) · Frontiers in Hematology · doi:10.3389/frhem.2026.1749376 · Cited by 2
Hong, D., Le, L., Chen, W., Long, W., & Fan, W. (2026) · EJNMMI Research · doi:10.1186/s13550-026-01373-4 · Cited by 2
“The patient had been diagnosed with diabetes for over three years and was receiving weekly subcutaneous injection of semaglutide (Ozempic) [1, 2], with satisfactory glycemic control (fasting blood glucose was 7.5, 6.8 and 7.0 mmol/L in the last three test) In October 2022, his initial PET/CT scan…”
InfluentialMetabolic Reprogramming of Urothelial Carcinoma—A Theragnostic Target for Betulinic Acid
Ganguly, A., Healy, K., Daugherty, S. L., Haldar, A., Kimura, S., Banerjee, R., Beckel, J. M., & Tyagi, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125598 · Cited by 2
Dang, D. X., Xu, S. Q., Li, D., Xia, X., & Xu, S. (2025) · Journal of Agriculture and Food Research · doi:10.1016/j.jafr.2025.102548 · Cited by 1
Extending Healthspan via GLP-1 Receptor Agonist: Insights and Perspectives
Chakrabarti, S. K., & Chattopadhyay, D. (2026) · Exploratory Research and Hypothesis in Medicine · doi:10.14218/erhm.2025.00036 · Cited by 1
Brubaker, J., Kim, S.-K., Li, B., Yang, M. Y., & Goddard, W. A. (2026) · Medicinal Chemistry Research · doi:10.1007/s00044-026-03579-6 · Cited by 1
Vastrad, B. M., & Vastrad, C. M. (2025) · Research Square · doi:10.21203/rs.3.rs-8076420/v1
Antsiferova, D. M., Ametov, A. S., Koteshkova, O. M. K., Ромашкина, Л. П., & Antsiferov, M. B. (2026) · Diabetes Mellitus · doi:10.14341/dm13441
Svorį mazinantys vaistai ir diabeto kontrole
Jamali, K. (2025) · Lithuanian University of Health Sciences
Buran, K., & Kalay, Ş. (2026) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1822102
Туркина, С. В. (2026) · Consilium Medicum · doi:10.26442/20751753.2026.5.203661
Delivery devices and container closure systems for co-formulated and co-administered biologics
Zhou, M., Duffy, K. H., Mitchener, C., Shi, G. H., & Collins, D. S. (2026) · Antibody Therapeutics · doi:10.1093/abt/tbag034
Ravi, T., Dash, K., Barman, D. K., Kwon, H., Mishra, M., & Sahoo, H. (2026) · Biopolymers · doi:10.1002/bip.70113
Metabolic Dysfunction–Associated Steatotic Liver Disease Reprograms the Hepatic Metastatic Niche
Karabicici, M., & Seki, E. (2026) · Seminars in Liver Disease · doi:10.1055/a-2921-0092
Eminent Effects of Glucagon-Like Peptide-1 Receptor Agonist on the Thyroid Gland of Male Albino Rats
Salama, R. M., Essawy, A. S., & Omar, M. A. E. R. (2026) · International Journal of Morphology · doi:10.4067/s0717-95022026000200542
Liang, W., Huang, Z., Long, Y., Chen, B., Yin, S., Li, Q., Li, H., 林麗黛, Quan, J., & Zhong, W. (2026) · Scientific Reports · doi:10.1038/s41598-026-63543-7
He, Y., Gao, J., Liu, Y., Wu, S., Kuang, J., Chen, D., Xu, B., Zhang, M., & Fang, Q. (2026) · Neuropharmacology · doi:10.1016/j.neuropharm.2026.111163
Ozempic: Use, Misuse, and Implications for the Treatment of Obesity.
Condrat, A. (2026) · Health Science Inquiry · doi:10.29173/24mnwh21
Lamah, E., Mudgal, M., Su, W., Jospeh, J., & Hijaz, M. (2026) · SSRN Electronic Journal · doi:10.2139/ssrn.7398818
Den, J., Nelson, N., Vaghjiani, R. G., & Klimberg, V. S. (2026) · Journal of Surgical Oncology · doi:10.1002/jso.70411 · Cited by 1
Khurshid, B., & Khurshid, S. (2025) · Review journal of neurological & medical sciences review. · doi:10.63075/fmkjkn28
Beyond a Molecular Link: Rethinking the Leptin–Leptin Receptor Axis in Thyroid Cancer
Hu, Y., Corcoy, R., & Mato, E. (2026) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2026.089696
“Glucagon-like peptide-1 receptor agonists (GLP-1RAs) may indirectly modify systemic leptin exposure through weight loss and changes in insulin resistance or inflammation, but they do not directly target the leptin–LEPR axis [50].”
GLP‐1 Receptor Agonists and Cancer Risk in Obesity Treatment
Hofseth, L. J., Murphy, E. A., Playdon, M. C., Makowski, L., Ibele, A. R., Fairman, C. M., & Hébert, J. R. (2026) · Obesity Reviews · doi:10.1111/obr.70247
Lakshmi, S. M., Singh, V., Vanangamudi, M., Taj, T., Shahin, H., Nath, R., Dutta, G., Avvari, S. K., Sridhar, S. B., Panigrahy, U. P., et al. (2026) · European Journal of Neuroscience · doi:10.1111/ejn.70718
Research progress in neural regulatory mechanisms and targeted therapy of obesity (Review)
Kang, D., Li, X., Zhang, Y., Sun, Y., Li, Y., Yao, Z., & Li, Y. (2026) · Molecular Medicine Reports · doi:10.3892/mmr.2026.14052
“…and biological activity of numerous bioactive molecules, including adipo‑ kines, inflammatory mediators, growth factors, enzymes and free Fa (85). as the primary energy storage organ, aT plays an essential role in regulating systemic energy metabolism, maintaining metabolic homeostasis and…”
Li, Z.-Z., Wu, J., Zhou, K., Yuan, Z., Luo, H.-Y., Liu, Y., Cao, L., Wang, G.-R., Liu, B., Wu, Q., et al. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103778
Metadata
- Authors
- Ibrahim, S. S., Ibrahim, R. S., Arabi, B., Brockmueller, A., Shakibaei, M., & Büsselberg, D.
- Affiliations
- Weill Cornell Medical College in Qatar (QA)
- Anatomische Anstalt (DE)
- Corresponding author
- Büsselberg, Dietrich
- ORCID
- Venue
- Cancer and Metastasis Reviews
- Published
- 2024-05-27
- Volume
- 43
- Issue
- 4
- Pages
- 1297-1314
- ISSN
- 0167-7659 (ISSN-L)
- 1573-7233
- PMC
- PMC11554930
- OpenAlex
- W4399046314
- Cited by
- 56
- References
- 125
- Citations by year
- 2026: 26 · 2025: 27 · 2024: 3
- FWCI
- 3.27
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Cancer and Metastasis Reviews (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PUBLISSO (German National Library of Medicine) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- Funders
- Qatar National Research Fund (NPRP 14S-0311–210033)
- Weill Cornell Medical College in Qatar
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- GLP-1 receptor agonists, obesity, type 2 diabetes, cancer, semaglutide, glucose homeostasis, beta-cell proliferation, insulin secretion, appetite regulation, cancer risk, signaling pathways
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Neoplasms, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.